Navigation Links
Sanofi Pasteur Receives Additional Order from U.S. Government to Produce Influenza A (H1N1) Vaccine
Date:9/21/2009

ide recommendations on the optimal dosage, number of doses and schedule.

Sanofi Pasteur operates influenza vaccine production facilities in the U.S. and in France. Production of the new A (H1N1) vaccine for HHS is being performed at the company's U.S.-based production facility.

About Influenza A (H1N1) 2009 Monovalent Vaccine

The U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine is an inactivated influenza virus vaccine indicated for active immunization of persons six months of age and older against influenza disease caused by pandemic (H1N1) 2009 virus.

The Influenza A (H1N1) 2009 Monovalent Vaccine is manufactured by the same process as Sanofi Pasteur's seasonal trivalent influenza virus vaccine licensed in the U.S. Influenza A (H1N1) 2009 Monovalent Vaccine is formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009 (H1N1) v-like virus. Influenza A (H1N1) 2009 Monovalent Vaccine is licensed for single-dose presentations in syringes and vials and in multi-dose vials. There is no preservative used in the singledose presentations. Multi-dose vials contain a preservative.

Safety Information for Influenza A (H1N1) 2009 Monovalent Vaccine

Influenza vaccine should not be administered to anyone with a known severe hypersensitivity to egg

proteins, any vaccine component or life-threatening reactions after previous administration of any

influenza vaccine. Recurrence of Guillain-Barre syndrome (GBS) has been temporally associated with the administration of influenza vaccine. The decision to give Influenza A (H1N1) 2009 Monovalent Vaccine to individuals who have a prior history of GBS should be based on careful consideration of the potential benefits and risks. Vaccination with Influenza A (H1N1) 2009 Monovalent Vaccine may not protect all individuals.

Before administering Influenza A (H1N1) 2009 Monoval
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. U.S. FDA Licenses Sanofi Pasteurs Pandemic Influenza Vaccine
2. Sanofi-Aventis Recognized for Workplace Efforts to Prevent Cancer
3. Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza
4. Beacon Equity Researches: Sanofi-Aventis, Amazon, Yahoo, Johnson & Johnson, Novavax and NexMed
5. Sanofi Pasteur Receives Order from U.S. Government to Produce New Influenza A(H1N1) Vaccine
6. U.S. FDA Licenses Sanofi Pasteurs New Influenza Vaccine Manufacturing Facility
7. Sanofi-aventis Announces Good First-quarter 2009 Performance
8. Sanofi-Aventis and Roche/Chugais Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013
9. Sanofi-aventis Affirms Its Commitment to Partnering with Local Communities to Improve Hispanic and African American Health
10. Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States
11. Paul Chew Appointed to sanofi-aventis U.S. Chief Science Officer/Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... A discovery by Northwestern Medicine scientists could lead to ... scarring in people with scleroderma. , Fibrosis, or ... tightening of the skin and lungs can lead to ... The concept for new therapeutic options centers on findings ... Medicine-Rheumatology, who identified the role that a specific protein ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... million older Americans suffer from depression, often brought on ... research a project that followed the lives of ... found that Internet use among the elderly can reduce ... , "That,s a very strong effect," said Shelia Cotten, ... and media who led the project. "And it all ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... Case Studies in the Management of PK/PD Data Will be Presented ... ... France, MOUNTAIN VIEW, Calif., Sept. 25 Pharsight,Corporation (OTC ... optimizing clinical drug development, today,announced that Dan Weiner, Ph.D., Senior Vice ...
... Call it Quits collaborative launches new Minnesota Clinic Fax Referral ... ... 25 Call it Quits,-- a newly named collaboration among Minnesota,s major ... it easier,for physicians and other healthcare providers to help their patients who,want ...
... the Cure(TM) Kicks Off October 1; Join the Breast ... Cancer Movement by Wearing Pink In October, DALLAS, Sept. ... together to increase awareness of breast cancer,a disease that without a ... you can join them. (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ) The ...
... Australian researcher has completed some pioneering work which is ... , Professor Patrick Tams 27-year exploration has mapped ... embryos. It reveals how cells direct themselves to ... He was (today) awarded recognition at a national conference ...
... PGL; Nasdaq: PGLA) announced today that its investigational,anti-cancer ... by the U.S. Food,and Drug Administration (FDA). The ... for the prevention of tumor recurrence following curative ... liver,cancer). Under the FDA Modernization Act of ...
... ARBOR, Mich. -- Despite decades of advances in diabetes ... likely than whites to have their blood sugar under ... nationally representative study finds. That puts them at a ... foot amputation and other long-term diabetes complications. , ...
Cached Medicine News:Health News:Pharsight to Host European Software Conference 2Health News:Health Organizations Join Forces Around Quit-Smoking Help 2Health News:Celebrities Pledge to Wear Pink, End Breast Cancer Forever With Susan G. Komen for the Cure 2Health News:Celebrities Pledge to Wear Pink, End Breast Cancer Forever With Susan G. Komen for the Cure 3Health News:Explorer completes the map ... for the body's blueprint 2Health News:US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 2Health News:US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 3Health News:Older blacks and Latinos still lag whites in controlling diabetes 2Health News:Older blacks and Latinos still lag whites in controlling diabetes 3Health News:Older blacks and Latinos still lag whites in controlling diabetes 4Health News:Older blacks and Latinos still lag whites in controlling diabetes 5
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
The best combination with the Haag-Streit 900 Slitlamps. For examination of the entire fundus, the vitreous and the iridocorneal angle. For newly born children. 10 mm internal diameter of the cornea ...
The best combination with the Haag-Streit 900 Slitlamps. For examination of the entire fundus, the vitreous and the iridocorneal angle. The classic Goldmann Glass....
For the binocular slit observation of the pupil, the macula, its surroundings out to 30 as well as the central vitreous body sections. Easy to use, lightweight glass provides a direct image....
... philosophy of the Quad 4™ Intramedullary Nailing ... that could be used for the widest ... of the system were to minimize the ... inventory, with one system that could address ...
Medicine Products: